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Background: The practice of making datasets publicly available for use by the wider scientific community has
become firmly integrated in genomic science. One significant gap in literature around data sharing concerns how it
impacts on scientists’ ability to preserve values and ethical standards that form an essential component of scientific
collaborations. We conducted a qualitative sociological study examining the potential for harm to ethnic groups,
and implications of such ethical concerns for data sharing. We focused our empirical work on the MalariaGEN
Consortium, one of the first international collaborative genomics research projects in Africa.
Methods: We conducted a study in three MalariaGEN project sites in Kenya, the Gambia, and the United Kingdom.
The study entailed analysis of project documents and 49 semi-structured interviews with fieldworkers, researchers
and ethics committee members.
Results: Concerns about how best to address the potential for harm to ethnic groups in MalariaGEN crystallised in
discussions about the development of a data sharing policy. Particularly concerning for researchers was how best
to manage the sharing of genomic data outside of the original collaboration. Within MalariaGEN, genomic data is
accompanied by information about the locations of sample collection, the limitations of consent and ethics
approval, and the values and relations that accompanied sample collection. For interviewees, this information and
context were of important ethical value in safeguarding against harmful uses of data, but is not customarily shared
with secondary data users. This challenged the ability of primary researchers to protect against harmful uses of
‘their’ data.
Conclusion: We identified three protective mechanisms – trust, the existence of a shared morality, and detailed
contextual understanding – which together might play an important role in preventing the use of genomic data in
ways that could harm the ethnic groups included in the study. We suggest that the current practice of sharing of
datasets as isolated objects rather than as embedded within a particular scientific culture, without regard for the
normative context within which samples were collected, may cause ethical tensions to emerge that could have
been prevented or addressed had the ‘ethical metadata’ that accompanies genomic data also been shared.
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Genomic studies generate vast amounts of data that are
investigated for significant associations between disease
phenotype and genetic variants, following a wider transition
in science from hypothesis-driven to data-driven research.
Characteristic of this development is the generation of
large, often publicly available datasets, the absence of spe-
cific hypotheses and the reliance on bioinformatics infra-
structure to manage and analyse these. In genomics
research, the need for very considerable sample numbers to
allow for the generation of sufficiently large datasets has
also meant that such research is increasingly collaborative
in nature.
When genomics research happens in collaborations,
data and samples are usually shared between collabora-
tors. In addition to this kind of sharing, genomic
researchers are also increasingly expected to share data
with researchers who were not initially involved in the
collaboration. The general expectation is that the utility
of genomic data is greatly increased when such data are
made available to the wider scientific community, and
that this will reduce the costs of research whilst simul-
taneously speeding up the process of scientific discovery
[1,2]. Furthermore, the sharing of data is expected to
reduce the number of people from whom samples need
to be collected afresh for research – thus reducing the
possibility for adverse events.
The sharing of data raises particular ethical issues,
many of which have been described in the literature.
The two main challenges identified are the possibility
that (knowledge about) individuals may be identified on
the basis of their genetic information [3,4] and that re-
searchers in resource-rich countries have an unfair advan-
tage in relation to researchers in poorer settings [5]. This
is particularly important when the research makes use of
samples that were collected by researchers in resource-
poor settings. A third challenge that has been identified
relates to the possibility that the sharing of genomic data
could cause stigma for the population groups involved in
the study [6].
To date, data sharing in genomics has not received the
kind of uptake that was anticipated [7]. One explanation
given is that data sharing practices sit uncomfortably
with research cultures that continue to reward publica-
tion of journal articles over the public release of data [8].
This suggests that the incentive to share is just one
amongst many for genomics researchers. Another ex-
planation is that shared data are of limited utility to
other researchers [7], particularly because secondary in-
formation about how the data were generated and
curated is usually omitted from the databases [9,10]. The
concept of ‘metadata’ refers to such additional informa-
tion that describes all the processes that lead to the
generation of the data that is being shared [11-13]. Suchprocesses include, for instance, the conditions under
which samples were obtained; the criteria used to iden-
tify disease phenotypes; the process followed for DNA
isolation; the methods, machines and chemicals used for
amplification and sequencing; and the curation and pro-
cessing of data prior to it being shared. Metadata allow
data users to assess the validity of the data [14] and to
place data in context. The absence of metadata can make
it difficult or impossible to use the genomic data.
One significant gap in literature around data sharing
concerns questions around how it impacts on scientists’
ability to maintain and preserve values and ethical stan-
dards that form an essential component of scientific col-
laborations. In this paper, we will describe how the
recognition of the importance of preserving high ethical
standards in the context of a requirement for data sharing
was identified and addressed in a large genomic collabor-
ation examining malaria, the MalariaGEN study. We also
show how it was in the context of requirements for data
sharing that the use of ethnicity data was identified as a
practical ethical issue requiring careful consideration.Ethnicity in data sharing
The MalariaGEN project spans research institutions
based in Africa, Asia and Europe, and is one of the few
large-scale genomic studies undertaken in Africa today.
Whereas genomic research has until recently tended to
focus on diseases affecting people in high-income coun-
tries, genomics research tools are now increasingly used
to investigate the genetic or molecular basis of complex
diseases in low-income countries including those on the
African continent. For a number of reasons the process-
ing, storage and analysis of the large numbers of samples
required for genomic studies in Africa tends to be located
in high-income settings outside Africa. To date, whilst
hundreds of Genome Wide Association (GWA) studies
have taken place focussing on a wide range of conditions,
hardly any of these have been applied to diseases that pri-
marily affect people in developing countries [15,16].
One methodological challenge facing genomics re-
search in Africa arises out of the high population diver-
sity present there. High population diversity constitutes
a methodological problem in genomic research that
needs addressing because of its potential to act as a con-
founder in such research [17], and this problem is more
pronounced when applying genomic methods to re-
search involving African participants [18]. One solution
used by researchers to address this problem is to stratify
the analysis of genomic data by ethnicity to ensure that
population structure can be accounted for in any ana-
lysis [19]. For this reason, the collection of genomic
samples and data in such studies includes the collection
of information about participants’ ethnicity.
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structuring of genomic analyses along ethnic or racial
lines has generated considerable concern amongst social
scientists and ethicists about the potential for stratified
genomic research results to increase stigmatisation of or
discrimination against the ethnic or racial groups in-
cluded in the studies [20,21]. Controversy surrounding
the use of samples from the Havasupai in the United
States [22,23] offers one example to indicate the possi-
bility that genomic research could harm the population
groups included in the research.
Methods
In this paper we draw on empirical data collected in a
study described in detail elsewhere [24]. For this study,
we conducted qualitative interviews with fieldworkers,
researchers, ethics committee members and representa-
tives of funding bodies in Kenya, The Gambia and the
United Kingdom. In addition to the interviewing compo-
nent of the study the current paper also draws on a
document analysis conducted on MalariaGEN project
documents. In preparing this manuscript, we have ad-
hered to the RATS guidelines [25].The MalariaGEN consortium
The MalariaGEN Consortium is a network of re-
searchers examining the genomic basis of resistance
against malaria (www.malariagen.net), the first phase of
which ran from 2005 to 2010. It incorporated approxi-
mately 50 principal investigators from Africa, Asia,
Europe and the United States, 30 of whom work at 18
different research institutions in Africa. The project in-
volved the genetic screening of samples from patients
suffering from malaria, and from unaffected (healthy)
children and adults.
MalariaGEN primary investigators have a variety of
disciplinary backgrounds, including human genetics,
paediatrics and epidemiology. It is a considerably hetero-
geneous group that comes together around a shared
interest in using whole-genome methods to study mal-
aria. Individuals pertaining to the MalariaGEN network
met frequently over the course of 5 years – network
meetings were organised on an annual basis, and a var-
iety of other workshops and events also brought to-
gether members of the network. Human genetic samples
were collected from MalariaGEN research participants
in a wide range of settings in Africa, ranging from rural
areas that are far removed from healthcare facilities, to
more urbanised settings with referral hospitals. Samples
were drawn from many different ethnic groups in Africa.
DNA extraction took place at the research institutes,
after which the DNA samples were exported to the UK
for processing.Data collection and analysis
Document analysis
In order to map the use of ethnicity as a topic of discussion
and concern in the MalariaGEN Consortium, we con-
ducted a textual analysis of MalariaGEN project documents
relating to ethnicity. A total of 54 project documents as well
as personal notes of meetings were analysed. The following
categories of documents were selected for this component
of the study: all documents pertaining to the organisation
of the MalariaGEN Consortium and the scientific studies;
documents pertaining to ethical discussions, and policy
documents where ethnicity was discussed. Included in the
study were the minutes of meetings of the MalariaGEN
programme management committee (18 documents),
meeting notes of four scientific workshops (4 documents),
reports and minutes of three ethics workshops (5 docu-
ments), documents regarding data release and data sharing
(20 documents) and research proposals and other project
policies (9 documents).
All project documents were coded manually in several
rounds of coding using a thematic, progressive coding
strategy [26]. Initially, all documents were read and all
instances where ethnicity was discussed were highlighted.
The highlighted text was then read and general topics
were identified, and notes made of these. In subsequent
rounds of coding, themes and sub-themes were identified
in the way in which ethnicity was discussed in the Consor-
tium. A draft of the initial analysis was circulated to se-
lected researchers in the MalariaGEN project to seek
comments and ensure the validity of our observations.
Interviews
We conducted 49 semi-structured interviews with vari-
ous stakeholders in the MalariaGEN project. A previous
article [24] described our analysis of this data in as far as
it pertains to issues relating to ethnic stigmatisation. We
conducted interviews with: MalariaGEN researchers (20
interviews); members of ethics committees who reviewed
MalariaGEN project proposals (12 interviews); fieldwor-
kers collecting MalariaGEN samples (15 interviews); and
with members of the funding bodies that supported
MalariaGEN research (2 interviews). MalariaGEN re-
searchers were interviewed at the time of project meetings
or research visits. Sixteen of the 20 MalariaGEN re-
searchers interviewed currently work in Africa, whilst 11
of these come from African countries. One researcher
works in the UK, and three others work in Asia. Inter-
views were conducted between June 2008 and October
2009, in the UK, The Gambia and Kenya (see De Vries
et al. 2012 for more information [24]). Interviews covered:
the current practice of using, defining and measuring eth-
nicity; awareness of particular ethical issues in using ethni-
city for genomics research; issues in identifying ethnic
groups and genomic data in research and publications;
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ing and re-use of ethnic data in genomics; and possible
solutions to the challenges identified. Topic guides were
adapted to suit the experience of the participants in the
four categories. Data was analysed iteratively throughout
this study, and interviews were conducted until no new
issues, themes or insights were generated during the in-
terviews or coding [27]. Interviews were recorded and
transcribed verbatim. Data were analysed inductively
using specialized software [28]. The first stage of open
coding was followed by hierarchical coding where emer-
ging patterns and themes in the data were established
[26]. Interpretations of the data were discussed amongst
the research team. Early insights were reviewed critic-
ally in subsequent rounds of coding and analysis to ex-
plore their authenticity and appropriateness. The use of
detailed fieldnotes was essential in this process to trace
the development of insights and understandings and
offer a means for critical reflection.
Ethics approval and consent
This study was reviewed and approved by the Oxford
Tropical Research Ethics Committee in the UK (OX 22-
08), the KEMRI/National Ethical Review Committee
(SCC4547) and The Gambia Government/MRC Labora-
tories Joint Ethics Committee (SCC1137v2). All inter-
viewees gave informed consent prior to the interview.
Consent was given for participation in the study, for re-
cording of the interview, and for the subsequent use of
anonymised quotes in research materials.
Results
Data sharing in MalariaGEN research: developing a data
sharing policy
In line with policy changes in the field of genomics
more widely [2], MalariaGEN researchers were required
to make their data publicly available for secondary use.
And, as is now common in genomics, the public release
of data was a condition of funding [29]. This required
MalariaGEN researchers to develop mechanisms and
policies for data release.
The MalariaGEN researchers developed a data sharing
policy in a number of distinct stages. First, researchers
developed a discussion paper describing the different
kinds of clinical and genomic data generated by the col-
laboration, and various options for regulating data ac-
cess. This discussion paper was circulated to funders,
MalariaGEN principal investigators, and ethics commit-
tees in Africa, Asia and Europe that had approved the
MalariaGEN study. Comments from all of these stake-
holders were considered in determining the most appro-
priate way to share the MalariaGEN genomic data. The
subsequent data release policy was again circulated to
the various stakeholders for input and finalisation.Two important ethical concerns about data sharing
practice emerged during the development of the draft
MalariaGEN data release policy. The first of these was a
concern that the unmediated sharing of data might have
the potential to disproportionately benefit researchers
outside of Africa, who had not contributed to sample or
data collection but who had the means to analyse vast
amounts of data much more quickly than those in low-
income countries who had played a key role in produ-
cing it. We have discussed this aspect of MalariaGEN’s
approach to data sharing elsewhere [5]. The second was
a concern about whether MalariaGEN data might have
the potential to be used in ways which could harm
ethnic groups and what might be done to minimise the
risk of this. In this paper we will focus on the second of
these issues.
Whilst there had been some discussion of the implica-
tions of ethnicity data earlier in the life of MalariaGEN,
concerns about the implications of using ethnicity
data became more prominent in discussions about
data sharing. Indeed, the very first document prepared
by the MalariaGEN researchers to discuss data sharing
identified the possibility of ‘ethnic stigmatisation’ – a
concern that had not been discussed by the re-
searchers before. The data release discussion paper,
which was prepared to describe the kinds of data that
were generated and to introduce the topic of data
sharing, read that
“any information on ethnic group, geographical
location or country linked to individual-level genetic
data could potentially provide a wealth of information
about the people in that ethnic group, location or
country.[…] the greater the detail of ethnic or other
demographic data that is linked to the genetic data
released, the greater the need to protect the ethnic
groups or communities involved, potentially through
restrictions on the use of the data” (Data Release
Discussion Paper, 2006).
This discussion document was circulated to a wide
range of people with an interest in the MalariaGEN pro-
ject, including the funding bodies and members of ethics
committees that had reviewed and approved MalariaGEN
studies. In response to this, one of the two MalariaGEN
funding bodies also explicitly questioned the potential that
MalariaGEN genomic data could be used to harm African
population groups. For instance, one member of a
MalariaGEN funding body queried
“are you comfortable that there is no risk in releasing
the open access data to all? I.e. [is there] no risk of
stigmatisation?” (Funding Body Representative email
to MalariaGEN, 2006).
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in the collaboration before discussions about data
release. What became clear in these discussions is
that MalariaGEN researchers considered themselves
under an obligation to protect individuals and com-
munities, and deliberated whether it would be pos-
sible and desirable to extend this obligation to other
data users.
“it may be appropriate to pass on an obligation to
the data users to only use the data for the purposes
of studying candidate genes in malaria resistance
and not to use the data in any way that may lead to
ethnic stigmatisation” (Data Release Discussion
Paper, 2006).
The researchers in the collaboration tried at this stage
to determine the best possible mechanism for data re-
lease. This included consideration of both a completely
open access option where information about ethnic
groups was coded, and a managed or restricted access
option. Our analysis showed that the ultimate decision
by MalariaGEN to adopt a ‘managed’ approach to data
access originated from a desire to exclude the possibility
of harm to ethnic groups that might have resulted from
the unrestricted release of genomic data. And although
various options for the release of genomics data were
discussed, researchers came to the view that data should
not be released for secondary research use without prior
vetting of secondary users and their proposed projects.
MalariaGEN researchers largely described themselves
as being strongly in favour of open access policies gen-
omic science, in the expectation that this would improve
the utility of data and lead to greater innovation.
“it makes the science move a lot faster and I also think
it is a good thing because otherwise the very few very
well funded labs basically get to dominate the
scientific discourse…” (R).
Researchers recognised that managing data access coun-
tered the prevailing norms and funders’ expectations, and
that it would be important for them to be able to provide
a very clear and strong justification for placing any restric-
tions on the release of data.
“including ethnic groups in the dataset is a concern
but [the Consortium] need(s) to be able to justify any
reduction in the level of information we release”
(Minutes of the 15th MalariaGEN Programme
Management Committee, 2006).
When asked for feedback on the proposed data release
policy, one MalariaGEN researcher commented that“it’s extremely difficult to judge the right point between
excessive release of data and undue concealment from
the international community” (PI Comments on
Second draft Data Release Policy, 2006).
In the end, after much deliberation, on balance, re-
searchers came to the view that their ‘obligation to pro-
tect’ meant that arguments in favour of a more managed
approach to data release outweighed those in favour of
‘open access’, and the decision was made to only release
data after review of proposals for secondary analysis by a
dedicated, independent data access committee.
Data sharing and changes in practice
On first impression, the decision to manage data access
for secondary use seemed puzzling – particularly as it was
made by a group of researchers who were vocally commit-
ted to the open access agenda. Were this commitment not
evident, it might have been tempting to draw the conclu-
sion that concerns about ethnic stigmatisation had simply
provided the researchers with a reason to restrict access to
project data. But this explanation was not credible given
the strength of the researchers’ commitment to open ac-
cess. Against this background, we were interested to inves-
tigate the factors explaining why concern over possible
harm to ethnic groups came to emerge in the context of
data sharing discussions in MalariaGEN and how it
came to influence the development of the model of
managed data release adopted. The interviews we con-
ducted were aimed at unraveling the reasons that could
explain our observations. In the remainder of this paper,
we will discuss why MalariaGEN researchers consider the
risk of harm to ethnic groups to be more pronounced
when data are analyzed by secondary researchers. We
identified three aspects of data sharing policies that re-
searchers considered problematic.
Data release and the relation to consent and ethics
approval
For MalariaGEN researchers, the requirement to share
data for secondary analysis of any kind was perceived to
be at least potentially incompatible with some aspects of
the specific consent that they obtained for their studies.
“the consent was that we were going to work on
malaria. So if it just turned into trying to find out
[other things] that is sort of betraying the confidence
that people give us to do this” (R).
Challenges to obtaining informed consent for research
in low-income countries have been well-documented
[30-32]. Many of these same challenges are also import-
ant when seeking consent to genomics research [33] and
interviewees in our project recognised these. Although
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genomic research is ethical, we have previously made an
argument that there is a need for additional safeguards
to protect participants in genomics research because of
challenges in obtaining appropriate informed consent
[5,33]. The researchers we interviewed in our study
seemed to reiterate this point. For instance,
“[you have] to be scrupulously honest to yourself as an
investigator and as a group of investigators with the
trust of the community and respecting the communities,
the things that people have entrusted you to do. I think
that is where we tend to operate rather than going to
every level of information at the consent level” (R).
Currently when data is shared through public databases,
they are shared according to the text that was written in
the consent documentation – for instance, if this identified
a particular cluster of diseases such as ‘infectious disease’,
then data ought only be shared for such research. How-
ever, what this does not do is acknowledge that some par-
ticipants may not have understood the documentation in
this detail and that consent may have been given on the
basis of trust. In addition to consent itself, the relation be-
tween ethics approval and secondary use was also identi-
fied as potentially problematic by interviewees. First of all,
ethics approval tends to be granted for a specific piece of
work, but when data are shared it can be used for many
different types of projects.
“Now a proposal received ethical review based on
what was presented […] now to look at these other new
areas being uncovered would not be ethical because
approval is given based on what was presented” (R12).
The challenge is not the sharing of genomic data per
se, but the absence of any scrutiny of secondary research
questions.
“we have nothing against getting data in a central
library. But what we are against is that unauthorized
usage of that data” (REC).
Understanding the intentions and values of unknown
secondary data users
The interviewees also identified the perceived anonymity
of the secondary data user, who is unknown to the primary
researchers and the ethics committees that approved data
release, as a potential problem. Within the MalariaGEN
collaboration, researchers know each other, share a com-
mitment to use genomic data to investigate a particular
disease and may even, despite their obvious diversity in
many respects, see themselves as sharing important rele-
vant values.“we know all the PIs, all the people working within
MalariaGEN and we have signed an agreement […]
and mostly we know them in term of their ethical you
know… And we know the probability of [abuse] is very
low […]. But outside us we don’t know anything about
people” (R).
Secondary users are often unknown to the primary re-
searchers, and there is no way to assess their values and
past behaviour. In addition, it is difficult to hold second-
ary users accountable.
“okay because somebody can sit in a sea in a boat, can
play with the data and can just [write] something very
bad about one ethnic group by using our data, by a
bad intention. It is just to avoid the bad intention
because… we are thinking about health and
participant protection, but somebody else won’t care
about that” (R).
There is, moreover, no possibility to investigate the in-
tentions of secondary researchers regarding re-analysis:
no scrutiny by ethics committees and no formalisation
of ethical obligations.
“The problem arises with what I want to call second
degree research. Because those are relying on […] the
Internet to make extrapolations and make their own
interpretations […]. That is a difficult person to
catch in terms of ethics because he will be doing
research from secondary materials. […] That is a
difficult person to catch and that is a big ethical
challenge” (REC1).
Another challenge identified by respondents is that
secondary data analysis does not require the formulation
of a hypothesis. Datasets can be mined for a wide range
of purposes and there is no incentive for secondary data
users to use data in accordance with the purpose for
which data was collected.
“those who collect they stay true to what they are
doing but it’s when it becomes available and then
people ask different questions and things which were
not intended or probably not even thought about by
those who designed the original studies that’s where
the problems generally arise” (R).
And datasets are not released in isolation; rather, it is
possible that other, complementary datasets are avail-
able that could be combined with the MalariaGEN
datasets to create a much richer source of information
about ethnic groups. This was also a concern for some
researchers.
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area and they compare […] sequence data from those
sorts of studies and find those traits present in
particular sub-groups of our population […] and write
a paper independently of anything to do with us be-
cause our information might be made publicly avail-
able then they could misinterpret or cause offence or
problems amongst sub-groups of the population […]
I: is that likely with this kind of data?
It depends, it all depends on what phenotypic and
other sort of data go along with it, how possible it is
for people to join up datasets” (R).
In literature, this has been referred to as the ‘data en-
vironment’ [34]. What our research revealed is that for
MalariaGEN researchers, the commitment to sharing
genomic data widely for a wide range of purposes raises
ethical concerns about possible harms that might arise
from secondary use.
Understanding the context of sample collection
A third and related ethical challenge in data sharing iden-
tified by respondents concerned the implications of the
absence of any accompanying contextual knowledge, what
we would like to call ‘ethical metadata’, when genomic
data are released. In data sharing, it is considered import-
ant that the datasets are ‘anonymous’: they are treated as
isolated and unlinked collections of genomic data that can
be transferred without any information on research partic-
ipants, their populations and the location and time of sam-
ple collection. When genomic data are shared, there is no
transfer of ‘embedded’ knowledge about groups, the ori-
ginal research project and questions, local relations and
sensitivities. The researchers we interviewed considered
this separation of the data from important contextual in-
formation potentially problematic.
“[The local scientist] understands better the cultural
background of the project and the communities and
all these kind of things. And the local scientist has
responsibility of considering the consequences of the
science that he does” (R).
MalariaGEN researchers collect samples in many rural
areas in Africa, and research participants are generally
characterized by relatively low income and education
levels [35]. Possibly because of this, many of the re-
searchers involved in the collaboration strongly per-
ceived themselves to have an obligation to protect
research participants from harm.
“these type of studies are profoundly embedded in a
culture, in a scientific attitude that is not[participants’] culture. […] In a sense we’re asking a lot
from them you know it’s a sort of carte blanche yes. So
you know ‘we don’t understand what you want us to
do but okay we trust [you]’” (R4).
For researchers, knowledge of the contextual features of
this ‘original’ trust relationship between research partici-
pants and the research team – such as for example, the
person who obtained consent - was essential in ensuring
that genomic data were analyzed appropriately. In addition,
understanding the relationships between ethnic groups in
the setting was seen to be important to ensure that genom-
ics research findings would be reported appropriately.
Where relationships between ethnic groups are strained,
for instance, it is more likely that those who knew about
this and understood its importance would take care when
reporting on genetic relatedness of groups.
Within the boundaries of the MalariaGEN research
collaboration, researchers felt confident that their insider
knowledge and values were appropriately articulated,
shared and respected.
“if I’m working in my small area then I know I’m
responsible for the status there and I have to keep it
this way…. when I agree to a big project like this then
a lot of things are going out of my hands but again the
same trust that the community posed in me, I’m
expecting that trust in this bigger project” (R).
But they were concerned that outside of the boundaries
and hence the shared values and practices of the Malaria-
GEN consortium, there was not the same degree of cer-
tainty that these values would be understood or respected.
Discussion
Mechanisms preventing harm in genomics research
Taken together, what interviewees seemed to be saying
was that when genomic datasets are shared with second-
ary users, they are generally shared as objects isolated
from important – and protective – normative context
and this raises particular ethical issues. Interviewees de-
scribed three problematic aspects of data sharing arising
out of this isolation, namely the relation to informed
consent and ethics approval; understanding the inten-
tions and values of unknown secondary data users; and
understanding the cultural background of sample do-
nors. Isolation from these aspects is important because
they form a ‘shared normative culture’ consisting of trust
relationships, a shared morality and in-depth under-
standing of the context of sample collection.
A first, and often largely implicit, component of the
normative culture in MalariaGEN is trust. Interviewees
identified trust relationships between participants and
their research team; between MalariaGEN researchers in
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committees. Trust between researchers included a
shared, mutual understanding that data will not be used
in ways that could harm research participants. The con-
sequence of violating this trust would likely be an end to
(future) collaboration – an important consequence in
the context of genomics research where collaboration is
essential for successful research. Trust between partici-
pants and the research team was described as important
by fieldworkers and researchers, and relates to a shared
obligation to protect research participants. In literature,
this perceived obligation has been termed ‘custodianship’
[8], which signifies that researchers often perceive them-
selves to be custodians of data or samples, on behalf of
communities or individuals that donated these. Trust
was also identified as an important aspect of the re-
search process by research ethics committee members.
In that case, the questions of trust related to REC mem-
bers’ expectation that researchers would respect the
terms and limitations of the ethics approval for their
project. The fact that researchers and ethics committee
members were often members of the same institution
was identified as significant in this respect. Even in the
absence of formal auditing mechanisms, it was seen as
vitally important for researchers to preserve their good
standing at their own institution, and to remain known
as a person of good moral standing.
A second component of the normative culture in Malar-
iaGEN is what we have chosen to call a shared morality be-
tween researchers [36]. This has much in common with the
role of trust because the possibility of trust is at least in part
based on a perceived mutual understanding of appropriate,
ethical behaviour and of the obligations of researchers to
participants, to each other and to research ethics commit-
tees. The respondents for this project shared views on im-
portant ethical issues such as maintaining confidentiality
and appropriate re-use of data. Importantly, researchers
also shared the ambition to investigate a disease that is det-
rimental to the wellbeing of many people in the developing
world. Together, the shared values and desire to increase
knowledge about a detrimental disease seems to constitute
the core of a shared morality. This shared morality is largely
implicit, but is also, on occasion, made explicit for instance
in the contracts drawn between the various institutions in
MalariaGEN or in the development of shared policies such
as those on data sharing or consent.
A third aspect of the normative culture in MalariaGEN is
detailed knowledge of the context of sample collection – or
the fact that there is always at least one person in the col-
laboration who might be consulted about this. Interviewees
identified two types of contextual knowledge to be import-
ant. The first of these was knowledge of the (limitations of)
consent and ethics approval given for the study. Knowing
what was approved, and having a reasonable understandingof participant expectations were identified as important in
preventing inappropriate research questions being investi-
gated. The important thing about this knowledge is that it
was always knowledge which included but went beyond
what was included in the form itself. The second type of
contextual knowledge identified by the interviewees relates
to detailed knowledge of the relations between, and cus-
toms and traditions of, the ethnic groups included in the
study. According to the interviewees, such knowledge is
essential in assessing the potential for research findings to
cause harm to ethnic groups and was a key factor inform-
ing the development of appropriate and sensitive practices.
Together, these three components of the normative
culture in MalariaGEN are seen by our interviewees to
provide a safeguard against harm. When data were to be
shared with people outside of the original collaboration,
researchers could no longer trust in the ethical common
ground to prevent harmful uses of data – calling into be-
ing concerns about ethnic stigmatisation. In order to ad-
dress such concerns, it may be necessary to accompany
genomic data with relevant information about the nor-
mative context of research. This could include for in-
stance information about the informed consent process
and the culture of and relations between ethnic groups.
We would like to call this information about ethical as-
pects of research ‘ethical metadata’. Just as metadata
provides information about the scientific processes that
led to data, ethical metadata would also provide infor-
mation about ethical aspects of genomic data. In this
sense, we believe our research echoes a call for greater
‘ethical reproducibility’ in biomedical research [37].
Conclusion
Data sharing is now the norm in genomics research. The
requirement for data sharing had profound implications
for the relationships and values within the MalariaGEN
research culture and required researchers to engage crit-
ically both with their own commitment to data sharing
and their sense of responsibility to research communities.
Ethical concerns over the use of ethnic data only emerged
in the context of discussions aimed at developing and put-
ting in place a policy for the wider release of data to the
international scientific community. In our investigation of
why this was the case, we identified a number of problem-
atic aspects of data sharing practices, namely limited abil-
ity to record and share information about informed
consent and ethics approval, difficulties in assessing the
intentions and integrity of secondary data users, and con-
cerns that secondary users could involuntarily inflict repu-
tational damage to population groups by not being
knowledgeable of the cultural background of and relations
between ethnic groups. Together these aspects are part of a
shared normative culture that is less mobile than the data
to which it refers. Within MalariaGEN, this normative
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The data presented in this paper were collected in the
context of a wider project that aimed to develop a better
understanding of the ethical issues raised by the use of
ethnic data in a particular genomics research in Africa.
We only interviewed scientists involved with this par-
ticular project, many of whom were clinicians primarily
and not genomic scientists. We recognise that clinicians
may experience a greater burden of care towards re-
search participants than people who simply see and ana-
lyse genomic findings. Whether and how, therefore, our
results are relevant to other scientists contributing to
genomics research projects needs further investigation.
By way of solution we would propose that at least some
information about the normative context of sample collec-
tion and data sharing – what we called ethical metadata –
needs to be taken into account when data sharing decisions
are to be made. This may particularly be the case where re-
search is conducted on identifiable population groups where
stigma or discrimination are of concern. Where there is
concern that data could harm population groups, it is our
view that, at a minimum, such data needs to be shared with
a description of the relevant features of the context within
which data was collected, and to which research results per-
tain. In addition to information about the consent process,
this would include information on ethics approval, and a de-
scription of the population groups involved in the research.Competing interests
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